The Drugs for Neglected Diseases Initiative (DNDI) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness (human African trypanosomiasis, HAT), Chagas disease,[1] malaria, paediatric HIV,[2] and specific helminth infections. DNDi's malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.
